MedTrace Logo

Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"

NCT02167893 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11288

Last updated 2017-03-29

Study results available
· View outcomes & findings →

Summary

The purpose of this survey is designed to evaluate the efficacy and safety of long-term use (96 weeks) of leuprorelin acetate SR 11.25 milligram (mg) injection kit (Leuplin SR 11.25 mg injection kit) in prostate cancer participants in daily medical practice.

Conditions

Interventions

DRUG

Leuprorelin acetate

Leuprorelin acetate SR 11.25 mg injection kit

Sponsors & Collaborators

Principal Investigators

  • Postmarketing Group Manager · Takeda

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2010-12-31
Completion
2010-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02167893 on ClinicalTrials.gov